Found: 57
Select item for more details and to access through your institution.
Central insulin action in energy and glucose homeostasis.
- Published in:
- Journal of Clinical Investigation, 2006, v. 116, n. 7, p. 1761, doi. 10.1172/JCI29063
- By:
- Publication type:
- Article
Enhanced PIP<sub>3</sub> signaling in POMC neurons causes K<sub>ATP</sub> channel activation and leads to diet-sensitive obesity.
- Published in:
- Journal of Clinical Investigation, 2006, v. 116, n. 7, p. 1886, doi. 10.1172/JCI27123
- By:
- Publication type:
- Article
Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors' reply.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2021, v. 54, n. 9, p. 1150, doi. 10.1111/apt.16608
- By:
- Publication type:
- Article
The obesity susceptibility gene Cpe links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake.
- Published in:
- Nature Medicine, 2009, v. 15, n. 10, p. 1195, doi. 10.1038/nm.2026
- By:
- Publication type:
- Article
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
- Published in:
- 2013
- By:
- Publication type:
- journal article
A guide to analysis of mouse energy metabolism.
- Published in:
- Nature Methods, 2012, v. 9, n. 1, p. 57, doi. 10.1038/nmeth.1806
- By:
- Publication type:
- Article
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 215, doi. 10.1111/dom.15307
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU‐ und US‐sourced reference insulins.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3817, doi. 10.1111/dom.15281
- By:
- Publication type:
- Article
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1351, doi. 10.1111/dom.14987
- By:
- Publication type:
- Article
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1011, doi. 10.1111/dom.14948
- By:
- Publication type:
- Article
Oral insulin: A history of ambition, failure and data torturing.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 940, doi. 10.1111/dom.14984
- By:
- Publication type:
- Article
Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 832, doi. 10.1111/dom.14932
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulinEquivalence‐3) study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1819, doi. 10.1111/dom.14768
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 713, doi. 10.1111/dom.14635
- By:
- Publication type:
- Article
Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 806, doi. 10.1111/dom.14636
- By:
- Publication type:
- Article
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 684, doi. 10.1111/dom.14632
- By:
- Publication type:
- Article
Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 196, doi. 10.1111/dom.14563
- By:
- Publication type:
- Article
Better glycaemic control with BioChaperone glargine lispro co‐formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1570, doi. 10.1111/dom.13685
- By:
- Publication type:
- Article
Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1140, doi. 10.1111/dom.13203
- By:
- Publication type:
- Article
Novel hepato-preferential basal insulin peglispro ( BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 4, p. 482, doi. 10.1111/dom.12834
- By:
- Publication type:
- Article
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 4, p. 489, doi. 10.1111/dom.12838
- By:
- Publication type:
- Article
Euglycaemic glucose clamp: what it can and cannot do, and how to do it.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 10, p. 962, doi. 10.1111/dom.12703
- By:
- Publication type:
- Article
InsR/FoxO1 Signaling Curtails Hypothalamic POMC Neuron Number.
- Published in:
- PLoS ONE, 2012, v. 7, n. 2, p. 1, doi. 10.1371/journal.pone.0031487
- By:
- Publication type:
- Article
Endothelial‐protective effects of a G‐protein‐biased sphingosine‐1 phosphate receptor‐1 agonist, SAR247799, in type‐2 diabetes rats and a randomized placebo‐controlled patient trial.
- Published in:
- British Journal of Clinical Pharmacology, 2021, v. 87, n. 5, p. 2303, doi. 10.1111/bcp.14632
- By:
- Publication type:
- Article
Single copy shRNA configuration for ubiquitous gene knockdown in mice.
- Published in:
- Nucleic Acids Research, 2005, v. 33, n. 7, p. e67, doi. 10.1093/nar/gni065
- By:
- Publication type:
- Article
Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus.
- Published in:
- Clinical Drug Investigation, 2023, v. 43, n. 2, p. 119, doi. 10.1007/s40261-022-01243-6
- By:
- Publication type:
- Article
FoxO1 Ablation in Hypothalamic Pomc Neurons Results in Lower Body Weight and Reduced Adipose Mass.
- Published in:
- Diabetes, 2007, v. 56, p. A7
- By:
- Publication type:
- Article
Peripheral hyperinsulinemia promotes tau phosphorylation in vivo.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Type 2 diabetes-like hyperglycemia in a backcross model of NZO and SJL mice: characterization of a susceptibility locus on chromosome 4 and its relation with obesity.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Agouti-related peptide–expressing neurons are mandatory for feeding.
- Published in:
- Nature Neuroscience, 2005, v. 8, n. 10, p. 1289, doi. 10.1038/nn1548
- By:
- Publication type:
- Article
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog<sup>®</sup> (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial.
- Published in:
- Clinical Pharmacokinetics, 2020, v. 59, n. 12, p. 1589, doi. 10.1007/s40262-020-00903-0
- By:
- Publication type:
- Article
The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 7, p. 1591, doi. 10.1007/s13300-020-00845-7
- By:
- Publication type:
- Article
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Myeloid Cell-Restricted Insulin Receptor Deficiency Protects Against Obesity-Induced Inflammation and Systemic Insulin Resistance.
- Published in:
- PLoS Genetics, 2010, v. 6, n. 5, p. 1, doi. 10.1371/journal.pgen.1000938
- By:
- Publication type:
- Article
Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data.
- Published in:
- Advances in Therapy, 2020, v. 37, n. 12, p. 4866, doi. 10.1007/s12325-020-01503-x
- By:
- Publication type:
- Article
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Comparison of Glucostatic Parameters After Hypocaloric Diet or Bariatric Surgery and Equivalent Weight Loss.
- Published in:
- Obesity (19307381), 2011, v. 19, n. 11, p. 2149, doi. 10.1038/oby.2011.134
- By:
- Publication type:
- Article
346-P: Predicting True Time to Recovery from Insulin-Induced Hypoglycemia with Dasiglucagon.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-346-P
- By:
- Publication type:
- Article
345-P: The Next Generation Glucagon Analog Dasiglucagon Consistently Achieves Rapid Recovery from Hypoglycemia across Subgroups.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-345-P
- By:
- Publication type:
- Article
344-P: Integrated Safety Analysis of Dasiglucagon for Treatment of Severe Hypoglycemia.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-344-P
- By:
- Publication type:
- Article
190-OR: Faster Recovery from Hyperglycemia with Ultrarapid Lispro (URLi) vs. Humalog in Patients with Type 1 Diabetes (T1D) on Continuous Subcutaneous Insulin Infusion (CSII).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-190-OR
- By:
- Publication type:
- Article
740-P: Proposed Biosimilar Gan & Lee Insulin Glargine (GL-GLA) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Glargine (IG).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-740-P
- By:
- Publication type:
- Article
738-P: Proposed Biosimilar Gan & Lee Insulin Aspart (GL-ASP) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) to U.S.- and EU-Licensed Insulin Aspart (ASP).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-738-P
- By:
- Publication type:
- Article
736-P: Proposed Biosimilar Gan & Lee Insulin Lispro (GL-LIS) Shows Pharmacokinetic (PK) and Pharmacodynamic (PD) Bioequivalence (BE) vs. U.S.- and EU-Licensed Insulin Lispro (LIS).
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-736-P
- By:
- Publication type:
- Article
1019-P: Variability of 501 Inhaled Insulin Absorption and Action.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1019-P
- By:
- Publication type:
- Article
988-P: MEDI0382, an Oxyntomodulin-Like Peptide with Targeted GLP-1/Glucagon Receptor Activity, Promotes a Dose-Dependent Increase in Gastric Emptying Time.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-988-P
- By:
- Publication type:
- Article
286-OR: Phase 3 Results for Dasiglucagon as a Fast and Effective Treatment for Severe Hypoglycemia.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-286-OR
- By:
- Publication type:
- Article
1107-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T1D.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1107-P
- By:
- Publication type:
- Article